Agastya Patel1, Piotr Spychalski1, Giulia Corrao2,3, Barbara A Jereczek-Fossa2,3, Robert Glynne-Jones4, Julio Garcia-Aguilar5, Jarek Kobiela1. 1. Department of General Surgery, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdańsk, Poland. 2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. 3. Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy. 4. Department of Radiation Oncology, Mount Vernon Cancer Centre, Northwood, UK. 5. Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: Short-course radiotherapy with consolidation chemotherapy (SCRT-CCT) has emerged as a promising alternative to the long course chemoradiotherapy (LCRT) regimen in locally advanced rectal cancer management. The systematic review and meta-analysis is aimed at summarizing current evidence on SCRT-CCT and comparing it to LCRT. MATERIAL AND METHODS: Electronic databases of MEDLINE, Web of Science, and Cochrane library were searched using a predefined search strategy returning 3314 articles. This review included 11 studies (6 randomized trials and 5 non-randomized studies) on SCRT-CCT regimen based on seven different cohorts. Weighted arithmetic means and forest plots were generated to determine summary estimates. RESULTS: The probability of achieving pathological complete response (pCR) was higher with SCRT-CCT compared to LCRT (risk ratio [RR] = 1.75, 95% confidence interval [CI]: 1.41-2.19). No statistically significant difference in 3-year overall survival (OS) was observed between the two groups (RR= 1.06, 95% CI: 0.98-1.14). The weighted arithmetic mean of 3-year OS and pCR was 83.6% versus 80.9%, and 24.5% versus 13.6% for SCRT-CCT and LCRT, respectively. R0 resection and T-downstaging rates ranged from 69.2-100% to 47-75% for SCRT-CCT, and 71-92.3% and 41-75% for LCRT, respectively. The regimens had similar compliance, postoperative, and late toxicity, however, acute toxicity rates varied primarily due to differences in treatment protocols. CONCLUSIONS: This review highlights the ability of SCRT-CCT to produce improved tumor response with comparable OS, R0 resection, and T-downstaging at the cost of increased acute toxicity. However, heterogeneity in treatment protocols across studies makes it difficult to provide definitive conclusions regarding the regimen. Several ongoing trials are expected to provide further evidence confirming the findings of RAPIDO trial and detail appropriate SCRT-CCT protocols to improve oncological outcomes, minimize toxicity, and determine its effectiveness as the standard-of-care for locally advanced rectal cancer patients.
BACKGROUND: Short-course radiotherapy with consolidation chemotherapy (SCRT-CCT) has emerged as a promising alternative to the long course chemoradiotherapy (LCRT) regimen in locally advanced rectal cancer management. The systematic review and meta-analysis is aimed at summarizing current evidence on SCRT-CCT and comparing it to LCRT. MATERIAL AND METHODS: Electronic databases of MEDLINE, Web of Science, and Cochrane library were searched using a predefined search strategy returning 3314 articles. This review included 11 studies (6 randomized trials and 5 non-randomized studies) on SCRT-CCT regimen based on seven different cohorts. Weighted arithmetic means and forest plots were generated to determine summary estimates. RESULTS: The probability of achieving pathological complete response (pCR) was higher with SCRT-CCT compared to LCRT (risk ratio [RR] = 1.75, 95% confidence interval [CI]: 1.41-2.19). No statistically significant difference in 3-year overall survival (OS) was observed between the two groups (RR= 1.06, 95% CI: 0.98-1.14). The weighted arithmetic mean of 3-year OS and pCR was 83.6% versus 80.9%, and 24.5% versus 13.6% for SCRT-CCT and LCRT, respectively. R0 resection and T-downstaging rates ranged from 69.2-100% to 47-75% for SCRT-CCT, and 71-92.3% and 41-75% for LCRT, respectively. The regimens had similar compliance, postoperative, and late toxicity, however, acute toxicity rates varied primarily due to differences in treatment protocols. CONCLUSIONS: This review highlights the ability of SCRT-CCT to produce improved tumor response with comparable OS, R0 resection, and T-downstaging at the cost of increased acute toxicity. However, heterogeneity in treatment protocols across studies makes it difficult to provide definitive conclusions regarding the regimen. Several ongoing trials are expected to provide further evidence confirming the findings of RAPIDO trial and detail appropriate SCRT-CCT protocols to improve oncological outcomes, minimize toxicity, and determine its effectiveness as the standard-of-care for locally advanced rectal cancer patients.
Authors: Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-11 Impact factor: 7.038
Authors: Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins Journal: BMJ Date: 2019-08-28
Authors: Emmanouil Fokas; Michael Allgäuer; Bülent Polat; Gunther Klautke; Gerhard G Grabenbauer; Rainer Fietkau; Thomas Kuhnt; Ludger Staib; Thomas Brunner; Anca-Ligia Grosu; Wolff Schmiegel; Lutz Jacobasch; Jürgen Weitz; Gunnar Folprecht; Anke Schlenska-Lange; Michael Flentje; Christoph-Thomas Germer; Robert Grützmann; Matthias Schwarzbach; Vittorio Paolucci; Wolf O Bechstein; Tim Friede; Michael Ghadimi; Ralf-Dieter Hofheinz; Claus Rödel Journal: J Clin Oncol Date: 2019-05-31 Impact factor: 44.544
Authors: Robert J Myerson; Benjamin Tan; Steven Hunt; Jeffrey Olsen; Elisa Birnbaum; James Fleshman; Feng Gao; Lannis Hall; Ira Kodner; A Craig Lockhart; Matthew Mutch; Michael Naughton; Joel Picus; Caron Rigden; Bashar Safar; Steven Sorscher; Rama Suresh; Andrea Wang-Gillam; Parag Parikh Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-15 Impact factor: 7.038
Authors: Lisette M Wiltink; Remi A Nout; Jochem R N van der Voort van Zyp; Heleen M Ceha; Marta Fiocco; Elma Meershoek-Klein Kranenbarg; Andreas W K S Marinelli; Cornelis J H van de Velde; Corrie A M Marijnen Journal: Clin Colorectal Cancer Date: 2016-02-13 Impact factor: 4.481
Authors: T H van Dijk; K Tamas; J C Beukema; G L Beets; A J Gelderblom; K P de Jong; I D Nagtegaal; H J Rutten; C J van de Velde; T Wiggers; G A Hospers; K Havenga Journal: Ann Oncol Date: 2013-03-22 Impact factor: 32.976